Bigmar, Inc. announces second quarter results.

COLUMBUS, Ohio--(BUSINESS WIRE)--August 14, 1996--Bigmar, Inc. (The Nasdaq Stock Market:BGMR) today reported unaudited financial results for the second quarter and six month periods ended June 30, 1996. (See attached table for detail.)

In comparing the current year's results with those in the same periods of 1995, it should be noted that 1996 results include the operations of two wholly-owned Swiss subsidiaries and one wholly-owned U.S. subsidiary: Bigmar Pharmaceuticals SA and Bioren SA, and Bigmar Therapeutics, Inc., respectively. In the 1995 periods, the Company consisted only of Bigmar Pharmaceuticals as Bioren SA was not yet acquired and Bigmar Therapeutics was not yet incorporated and essentially had no operations. It should also be noted that on June 26, 1996, Bigmar completed an initial public offering of 1,610,000 shares. As such, there were 2,585,000 and 2,481,000 shares outstanding in the second quarter and six month periods of 1996, respectively, compared to 400,168 outstanding in both 1995 periods.

Net sales in the 1996 second quarter and six month periods increased 44% and 116%, respectively, from the same periods in 1995, reflecting the sales contributions from Bioren, slightly offset by an 8% second quarter and a 4% first half fluctuation in the exchange rate between value of the U.S. dollar and French franc. It should be noted that sales in the 1995 first half included approximately $1,000,000 from prostate materials. The Company has sold no prostate materials in 1996 as it has focused on higher margin infusion solutions and oncology product sales.

Although Bigmar was profitable in both the second quarter and six month periods of 1996, lower net income in these periods compared to the 1995 same periods primarily reflects higher selling, general and administrative and research and development expenses related to the inclusion of Bioren, as well as higher interest expense. In line with the Company's focus on generic oncology drug development and manufacturing, research and development expenses reflect the Company's efforts to prepare its new oncology drug production facility in Switzerland for validation as well as oncology product development costs.

John Tramontana, President and CEO of Bigmar, commented, "The second quarter of 1996 has been one of great accomplishment. We completed a successful IPO in which we raised net proceeds of $9.4 million to support the Company's growth strategy. We also moved forward on our generic oncology drug program. In this regard, in May and July 1996, we brought on board Al Hodge and Peter Stoelzle, respectively, both pharmaceutical industry professionals with strong track records in generic drug approvals and manufacturing compliance. The second half of 1996 should also be exciting as we begin marketing additional generic oncology products, continue development of our proprietary products and, by year-end, expect to begin production at our new Swiss facility."

All forward looking information are estimates by the Company's management and are subject to various risks and uncertainties that may influence the Company's development and manufacturing efforts, as well as other risks as detailed from time to time in the Company's SEC reports and filings.

BIGMAR, Inc.'s strategy is to supply world markets with a full line of high quality, affordably priced generic and proprietary oncology products. Over next 24 months, the Company intends to manufacture, in its state-of-the-art facilities in Switzerland, and market several generic oncological drugs and to manufacture and market additional oncological drugs as their patents expire. The Company currently manufactures and markets intravenous infusion solutions in Switzerland, and markets in Germany two oncological products as well as raw materials used to manufacture medications for the treatment of prostate enlargement. -0-

                   BIGMAR, INC. AND SUBSIDIARIES
              CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                          (In U.S. Dollars)
                             (Unaudited)

                          Three Months Ended     Six Months Ended
                               June 30,               June 30,
                           1996        1995      1996        1995(a)

Net Sales           $  1,940,062  $  591,239  $  3,838,064  $  1,776,949

Cost of Sales          1,212,094     350,755     2,363,193     1,410,710

Gross Profit             727,968     240,484     1,474,871       366,239

Operating Expenses:

Research and Development  97,291         --        185,685           --

  Selling, General and
   Administrative        510,321      36,597     1,033,689        58,049

Total operating
 expenses                607,612      36,597     1,219,374        58,049

Operating Income         120,356     203,887       255,497       308,190

Interest Income
 (Expense)             (112,983)     (9,673)      (196,443)        (505)

Other income
 (Expenses)                  22          -              22            -

Income Before Taxes       7,395    194,214          59,076      307,685

Taxes                       191     39,118             191       61,818

Net Income             $  7,204  $ 155,096     $    58,885    $ 245,867

Earnings per share:

  Primary                  --       $0.39           $0.02        $0.61
  Fully Diluted            --       $0.39           $0.02        $0.61

Average number of common
 shares outstanding
  Primary                2,585,000    400,188    2,481,154     400,188
  Fully diluted          2,585,000    400,188    2,481,154     400,188

(a) Prior to Company's public offering on June 26, 1996.

CONTACT: Bigmar, Inc.

Gerald Sweeney, CFO

[phone]

or

Bigmar's Investor Relations Counsel

The Equity Group, Inc.

Tamara Ehlin

[phone]

email: equityny@[e-mail]